11.70
-5.875(-33.43%)
Currency In USD
| Previous Close | 17.58 |
| Open | 15.05 |
| Day High | 17.5 |
| Day Low | 10.52 |
| 52-Week High | 18.35 |
| 52-Week Low | 5 |
| Volume | 774,164 |
| Average Volume | 31,034 |
| Market Cap | 14.76M |
| PE | -0.55 |
| EPS | -21.29 |
| Moving Average 50 Days | 9.27 |
| Moving Average 200 Days | 8.54 |
| Change | -5.88 |
If you invested $1000 in Sensei Biotherapeutics, Inc. (SNSE) since IPO date, it would be worth $30.95 as of October 19, 2025 at a share price of $11.7. Whereas If you bought $1000 worth of Sensei Biotherapeutics, Inc. (SNSE) shares 3 years ago, it would be worth $395.27 as of October 19, 2025 at a share price of $11.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
GlobeNewswire Inc.
Oct 17, 2025 12:00 PM GMT
6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort –Favora
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025
GlobeNewswire Inc.
Sep 23, 2025 11:30 AM GMT
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it wil
Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John C